Michael J Miller

Company: Glycadia Inc.

Job title: Scientific Advisory Board

Seminars:

Addressing the Role of Glycated Albumin Non-Enzymatic Glycation in Retinal Vascular Diseases: GLY-230 2:15 pm

Compelling preclinical evidence of reversal of diabetic retinal vascular disease pathologies Sharing a reversal in abnormal biomarkers (including VEGF) with a small molecule given orally and/or with multimodal administration possibilities GLY-230 reverses in the documented direct pathogenic actions of glycated albumin (GA) and decreases in generation of AGEs which are also pathogenic in RVDRead more

day: Day One